1
Improved Pharmacokinetics
Increases solubility and oral absorption for poorly soluble drugs, enabling higher and more consistent exposure, tolerability, and consequently adherence and efficacy.
Our Transformative Approach
Revolutionizing Drug Development Through LADR
Starting with drug substances already approved for human use, LADR applies a modifying agent from a curated library to create an improved, patentable drug. LADR is a chemical modification approach, not a formulation, and does not trigger a 505(b)(1) path.
What Makes LADR Different
A development model built around practical acceleration and disciplined risk.
LADR Platform: An Expansive Drug Upgrade Engine
Proven approach that can transform dozens of legacy drugs into patentable, 505(b)(2)-ready prodrugs for new indications across oncology, CNS, and CV/metabolic.
2
Chemical Modification, Not Formulation
Covalent prodrug strategy—not a salt, solvate, or excipient tweak—supporting composition-of-matter protection for each LADR derivative.
3
Broad Chemotype Applicability
Proven across multiple scaffolds (taxanes, TKIs, catechols, sedatives), enabling pipeline expansion in oncology, CV/metabolic, and CNS.
4
Composition of Matter Patent Protection
Each LADR prodrug can be covered by a new USPTO and Global composition-of-matter patent with up to 20 years of patent term from filing.
5
Regulatory Efficiency and Exclusivity Upside
LADR prodrugs follow a 505(b)(2) development strategy, leveraging established Reference Listed Drug data to reduce time and capital as compared to de novo drug development; select programs are engineered to pursue NME status and associated 7/5-year exclusivity.
Faster. Capital Efficient. De-Risked.
Ladrion's LADR 505(b)(2) strategy is designed to create multiple value inflection points across IND, human PoC, partnership, and approval within a single funding lifecycle.
De-risked development: FDA 505(b)(2) pathway references existing RLD safety/efficacy data – no need to repeat decades of prior work.
Orphan acceleration: 7-year exclusivity per indication + fast-track designation potential.
Real IP protection: Composition-of-matter patents (up to 20 years) + 5-year NCE exclusivity upside where FDA deems new active moiety.
Capital efficiency: Four rare-disease shots on goal for the cost of one traditional Phase 2 trial.
Years to FDA Approval
Development Timeline Comparison
Research
Clinical Trials
NDA Review
De Novo 505(b)(1)
14-16 years
5
9
2
Typical 505(b)(2)
8-9 years
2
5.5
1
Ladrion LADR 505(b)(2) Strategy
4-5 years
1
3
0481216
Ladrion can deliver partnerable, approval-oriented data packages in under 5 years—fast enough to create multiple value inflection points (IND, Human PoC, Partnership, Approval) within a single funding lifecycle.
Validated Science
Not just a concept…The LADR platform has been validated by third-party biotech firms, vetted and financed by sophisticated investors.